SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (9380)3/25/1999 11:01:00 AM
From: Arthur Radley  Read Replies (2) | Respond to of 17367
 
Just when I was beginning to think nothing positive will come from the small biotechs, along comes DRMD. Yes! There is still hope for us Xomer's.



To: Bluegreen who wrote (9380)3/28/1999 2:19:00 PM
From: aknahow  Respond to of 17367
 
I would hope it would replicate the P II zero deaths. However we are at or above 373 accruals and I would think that statistical significance can be demonstrated even with deaths in the treatment group.

That is why I would like someone like Cacaito to calculate out what specific numbers of deaths in both groups would by themselves give proof of statistical significance.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News